These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35973038)

  • 1. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
    Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
    Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
    Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
    Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Detection of Cancer-Testis Antigen PRAME.
    Lezcano C; Müller AM; Frosina D; Hernandez E; Geronimo JA; Busam KJ; Jungbluth AA
    Int J Surg Pathol; 2021 Dec; 29(8):826-835. PubMed ID: 33890816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.
    Cammareri C; Beltzung F; Michal M; Vanhersecke L; Coindre JM; Velasco V; Le Loarer F; Vergier B; Perret R
    Virchows Arch; 2023 Aug; 483(2):145-156. PubMed ID: 37477762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.
    Šafanda A; Kendall Bártů M; Michálková R; Stružinská I; Drozenová J; Fabián P; Hausnerová J; Laco J; Matěj R; Škapa P; Švajdler M; Špůrková Z; Méhes G; Dundr P; Němejcová K
    Virchows Arch; 2023 Oct; 483(4):509-516. PubMed ID: 37610627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis.
    Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP
    Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
    Coppock JD; Gradecki SE; Mills AM
    Int J Gynecol Pathol; 2023 Jan; 42(1):35-42. PubMed ID: 35512215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological features of metastatic melanoma in effusion cytology of serosal cavity].
    Xia Q; Chang XN; Huang B; Li XF; Luo DJ; Wang QJ; Jiang MT; Fan J; Zhou DW
    Zhonghua Bing Li Xue Za Zhi; 2024 Aug; 53(8):837-842. PubMed ID: 39103266
    [No Abstract]   [Full Text] [Related]  

  • 10. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).
    Grillini M; Ricci C; Pino V; Pedrini S; Fiorentino M; Corti B
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):14-18. PubMed ID: 34508017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
    Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
    Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
    Turner N; Ko CJ; McNiff JM; Galan A
    Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
    Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
    Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry for PRAME in Dermatopathology.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
    Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
    Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
    Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
    J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
    Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
    Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
    Cassalia F; Danese A; Tudurachi I; Federico S; Zambello A; Guidotti A; Franceschin L; Bolzon A; Naldi L; Belloni Fortina A
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.